Lannett manufacturing capacity balloons to 522,000 sq. ft. in short order

A few months ago, Philadelphia-based generics drugmaker Lannett ($LCI) was a little-known company with a single 31,000-square-foot manufacturing site. Now, with a couple of deals, it has three facilities in three states comprising 522,000 square feet of capacity and broken on the national scene with a $1.23 billion deal to buy UCB's U.S.-based generics operations.

Lannett Wednesday announced the deal to buy Kremers Urban Pharmaceuticals from Belgium-based UCB. With that it gets a portfolio of 18 products, but it also gets Kremers 381,000-square-foot facility in Seymour, IN, which Lannett says has substantial manufacturing and warehousing capacity as well as dedicated product development space.

Lannett CEO Arthur Bedrosian

"KU brings considerable manufacturing capacity, a first class research and development team and the potential for advancing our active pharmaceutical ingredients business," Lannett CEO Arthur Bedrosian said in a statement. He said the Kremers Urban will boost Lannett's regulatory expertise, particularly in the areas of difficult-to-manufacture products and Paragraph IV certifications.

In June, Lannett added liquid manufacturing and over-the-counter products to its portfolio with pickup of Silarx Pharmaceuticals for an undisclosed amount. Silarx specializes in liquid products, both generic prescriptions and over-the-counter, which are manufactured at its 110,000-square-foot facility in Carmel, NY.

While the Kremers Urban deal will introduce the company to a much wider pharma audience, Lannett has already caught the attention of the feds. It has announced that it received a subpoena from the Justice Department, which is known to be conducting a criminal investigation into generic drug pricing across the industry.

Fortune magazine recently noted it is the fastest growing company in the country. While its 2014 revenues were just $274 million, it had a 3-year annual growth rate for earnings of 314%. It achieved that in part with aggressive pricing of niche generic products. Fortune pointed out that Lannett's prices on cardiovascular and migraine meds more than doubled last year, with 150% and 124% increases.

- here's the Lannett release

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.